Griffin Securities’ Keith Markey on the Promise of RNAi and Synthetic Biologics
October 08, 2014 at 19:28 PM EDT
The Life Sciences Report: Keith, Griffin Securities’ portfolio seems weighted toward high-science, but high-risk, therapeutic ideas. How would you describe your investment philosophy? Keith Markey: We look for truly innovative products. These products come . . . → Read More: Griffin Securities’ Keith Markey on the Promise of RNAi and Synthetic Biologics Similar Articles: A Tour of Australian Biotechs with Morgans’ Scott Power Shortage of R&D at Big Pharma Creates Demand for Small Biotech: Joseph Pantginis Four Hidden Australian Life Sciences Growth Stocks Revealed: Scott Power